Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cortexyme stock | $63.05

Learn how to easily invest in Cortexyme stock.

Cortexyme Inc is a biotechnology business based in the US. Cortexyme shares (CRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cortexyme employs 37 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Cortexyme

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cortexyme stock price (NASDAQ: CRTX)

Use our graph to track the performance of CRTX stocks over time.

Cortexyme shares at a glance

Information last updated 2021-10-16.
Latest market close$63.05
52-week range$26.66 - $121.98
50-day moving average $89.20
200-day moving average $62.30
Wall St. target price$108.43
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.94

Buy Cortexyme shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cortexyme stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cortexyme price performance over time

Historical closes compared with the close of $63.05 from 2021-10-15

1 week (2021-10-08) -27.93%
1 month (2021-09-17) -28.18%
3 months (2021-07-16) 17.76%
6 months (2021-04-16) 62.92%
1 year (2020-10-16) 27.45%
2 years (2019-10-16) 173.30%
3 years (2018-10-13) N/A
5 years (2016-10-13) N/A

Cortexyme financials

Gross profit TTM $0
Return on assets TTM -28.86%
Return on equity TTM -50.01%
Profit margin 0%
Book value $4.79
Market capitalisation $1.9 billion

TTM: trailing 12 months

Shorting Cortexyme shares

There are currently 2.6 million Cortexyme shares held short by investors – that's known as Cortexyme's "short interest". This figure is 1.5% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting Cortexyme shares can be evaluated.

Cortexyme's "short interest ratio" (SIR)

Cortexyme's "short interest ratio" (SIR) is the quantity of Cortexyme shares currently shorted divided by the average quantity of Cortexyme shares traded daily (recently around 228186.25218914). Cortexyme's SIR currently stands at 11.42. In other words for every 100,000 Cortexyme shares traded daily on the market, roughly 11420 shares are currently held short.

However Cortexyme's short interest can also be evaluated against the total number of Cortexyme shares, or, against the total number of tradable Cortexyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cortexyme's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Cortexyme shares in existence, roughly 90 shares are currently held short) or 0.1455% of the tradable shares (for every 100,000 tradable Cortexyme shares, roughly 146 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cortexyme.

Find out more about how you can short Cortexyme stock.

Cortexyme share dividends

We're not expecting Cortexyme to pay a dividend over the next 12 months.

Cortexyme share price volatility

Over the last 12 months, Cortexyme's shares have ranged in value from as little as $26.6612 up to $121.98. A popular way to gauge a stock's volatility is its "beta".

CRTX.US volatility(beta: 0.92)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cortexyme's is 0.9179. This would suggest that Cortexyme's shares are less volatile than average (for this exchange).

Cortexyme overview

Cortexyme, Inc. , a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California. .

Frequently asked questions

What percentage of Cortexyme is owned by insiders or institutions?
Currently 33.086% of Cortexyme shares are held by insiders and 63.114% by institutions.
How many people work for Cortexyme?
Latest data suggests 37 work at Cortexyme.
When does the fiscal year end for Cortexyme?
Cortexyme's fiscal year ends in December.
Where is Cortexyme based?
Cortexyme's address is: 269 East Grand Avenue, South San Francisco, CA, United States, 94080
What is Cortexyme's ISIN number?
Cortexyme's international securities identification number is: US22053A1079
What is Cortexyme's CUSIP number?
Cortexyme's Committee on Uniform Securities Identification Procedures number is: 22053A107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site